

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
<b>TRANSMITTAL LETTER TO THE UNITED STATES</b> <b>DESIGNATED/ELECTED OFFICE (DO/EO/US)</b> <b>CONCERNING A FILING UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER <b>BSW-1</b>	
INTERNATIONAL APPLICATION NO. <b>PCT/AU00/00363</b>		INTERNATIONAL FILING DATE <b>26 April 2000 (26.04.2000)</b>	
U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <b>10/019356</b>		PRIORITY DATE CLAIMED <b>21 April 1999 (21.04.1999)</b>	
TITLE OF INVENTION <b>A METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR NEOPLASTIC STATES IN MAMMALS</b>			
APPLICANT(S) FOR DO/EO/US <b>SLATER, Michael; BARDEN, Julian</b>			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2))           <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> </ol>			
<b>Items 13 to 20 below concern document(s) or information included:</b>			
<ol style="list-style-type: none"> <li>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98</li> <li>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>17. <input type="checkbox"/> A substitute specification</li> <li>18. <input type="checkbox"/> A change of power of attorney and/or address letter</li> <li>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail</li> <li>23. <input checked="" type="checkbox"/> Other items or information:</li> </ol>			
<b>Request for the Recording of a Change</b> <b>Article 34 Amendments included in IPER</b> <b>Express Mail Label No. EL390884699US</b> <b>Filed On: 22 October 2001 (22.10.01)</b>			

U.S. APPLICATION NO. (IF KNOWN) <b>10/019336</b>		INTERNATIONAL APPLICATION NO <b>PCT/AU00/00363</b>		ATTORNEY'S DOCKET NUMBER <b>BSW-1</b>	
--	--	---	--	--	--

24. The following fees are submitted:				<b>CALCULATIONS PTO USE ONLY</b>	
<b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :</b> <input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO . . . . . <b>\$1000.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO . . . . . <b>\$860.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . . . <b>\$710.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) . . . . . <b>\$690.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) . . . . . <b>\$100.00</b> <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$1,000.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				<b>\$130.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	74 - 20 =	54	x \$18.00	<b>\$972.00</b>	
Independent claims	2 - 3 =	0	x \$80.00	<b>\$0.00</b>	
Multiple Dependent Claims (check if applicable). <input checked="" type="checkbox"/>				<b>\$270.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$2,372.00</b>	
<input checked="" type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				<b>\$1,186.00</b>	
<b>SUBTOTAL =</b>				<b>\$1,186.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				<b>\$0.00</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$1,186.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,186.00</b>	
				Amount to be:	\$
				refunded	\$
				charged	\$

a. ☒ A check in the amount of **\$1,186.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **50-0311** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

TRIANO III, Nicholas P.  
 Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C.  
 One Financial Center  
 Boston, Massachusetts 02111  
 United States of America

  
 SIGNATURE  
**TRIANO III, Nicholas P.**  
 NAME  
**36, 397**  
 REGISTRATION NUMBER  
**21 October 2001 (21.10.01)**  
 DATE

Express Mailing Label No. **EL390884699US**  
Date of Deposit: **October 22, 2001**

107019356

Attorney Reference No. BSW-1

**531 Rec'd PC...** **22 OCT 2001**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Michael Slater *et al.*  
APPLICATION NUMBER: Not yet assigned  
FILING DATE: October 22, 2001  
FOR: A METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR NEOPLASTIC STATES IN MAMMALS

EXAMINER: Not yet assigned  
ART UNIT: Not yet assigned

#3/a

October 22, 2001  
Boston, Massachusetts

Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Prior to an action on the merits, Applicants respectfully request that the following amendments be entered in the above-referenced application.

***In the Claims:***

Please cancel claim 7 without prejudice or disclaimer.

Please amend claims 2, 4-6, 8-11, 14-17, 19-23, 27-32, 37-40, 43-45, 48-50, and 55-56 as follows:

2. (amended once) A method of determining the aetiology of carcinogenesis in a mammal, comprising detecting the P2X purinergic receptor expression profile of cells and/or tissue from the mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.
4. (amended once) A method according to claim 1 or claim 2 wherein the cells are prostate tissue cells.
5. (amended once) A method according to claim 1 or claim 2 wherein the cells are breast tissue cells.
6. (amended once) A method according to claim 1 or claim 2 wherein the cells are obtained by biopsy.
8. (amended once) A method according to claim 1 or claim 2 wherein the cells are obtained from abody fluid, from digital rectal examination exudate and/or from semen.

Applicant: Slater *et al.*

9. (amended once) A method according to claim 1 or claim 2 wherein detection of the P2X purinergic receptor expression profile comprises use of an antibody reagent.
10. (amended once) A method according to claim 1 or claim 2 wherein the detection of the P2X purinergic receptor expression profile comprises use of a P2X antibody reagent specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
11. (amended once) A method according to claim 5 wherein the detection of the P2X purinergic receptor expression profile comprises use of an antibody reagent specific for P2X<sub>2</sub> or P2X<sub>3</sub>.
14. (amended once) A method according to any one of claims 9, 12 or 13 wherein the antibody reagent comprises a polyclonal antiserum.
15. (amended once) A method according to any one of claims 9, 12 or 13 wherein the antibody reagent comprises a monoclonal antiserum.
16. (amended once) A method according to any one of claims 9, 12 or 13 wherein the antibody reagent is a suite of polyclonal antibodies.
17. (amended once) A method according to any one of claims 9, 12 or 13 wherein the antibody reagent is a suite of monoclonal antibodies.
19. (amended once) A method according to any one of claims 1, 2, 12 or 13 wherein detection of the P2X receptor expression profile is by immunohistochemical means.
20. (amended once) A method according to any one of claims 1, 2, 12 or 13 wherein detection of the P2X receptor expression profile is by ELISA.
21. (amended once) A method according to any one of claims 1, 2, 12 or 13 wherein detection of the P2X receptor expression profile is by RIA.
22. (amended once) A method according to any one of claims 1, 2, 12 or 13 wherein the detection of the P2X receptor expression profile is by Western bolt.
23. (amended once) A method according to any one of claims 1, 2, 12 or 13 wherein detection of the P2X purinergic receptor expression is by detection of P2X purinergic receptor mRNA.
27. (amended once) Use according to claim 24 or claim 25 wherein the P2X purinergic receptor antibody reagent comprises a polyclonal antiserum.
28. (amended once) Use according to claim 24 or claim 25 wherein the P2X purinergic receptor antibody is a monoclonal antiserum.

29. (amended once) Use according to claim 24 or claim 25 wherein the P2X purinergic receptor antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
30. (amended once) Use according to claim 24 or claim 25 wherein the P2X purinergic receptor antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, or P2X<sub>7</sub>.
31. (amended once) Use according to claim 24 or claim 25 wherein the P2X purinergic receptor antibody reagent is a suite of polyclonal antibodies.
32. (amended once) Use according to claim 24 or claim 25 wherein the P2X purinergic receptor antibody reagent is a suite of monoclonal antibodies.
37. (amended once) An isolated mammalian cell or tissue sample according to claim 34 wherein the P2X purinergic receptor-specific antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
38. (amended once) An isolated mammalian cell or tissue sample according to claim 34 wherein the P2X purinergic receptor-specific antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, or P2X<sub>7</sub>.
39. (amended once) A kit for diagnosing a pre-neoplastic and/or neoplastic state in a mammal comprising components for detection of P2X purinergic receptor expression profile in a sample comprising cells and/or tissue from the mammal and means for comparison of the expression level with a predetermined expression level.
40. (amended once) A kit according to claim 39 wherein one of the components is an antibody reagent specific for a P2X purinergic receptor.
43. (amended once) A kit according to claim 41 or claim 42 wherein the P2X purinergic receptor antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
44. (amended once) A kit according to claim 41 or claim 42 wherein the antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> or P2X<sub>7</sub>.
45. (amended once) A kit according to claim 40 wherein the P2X purinergic receptor expression profile is detected by a colorimetric assay.
48. (amended once) A kit according to claim 39 wherein the sample is a body fluid.
49. (amended once) A kit according to claim 39 wherein the sample is a digital rectal examination exudate.
50. (amended once) kit according to claim 39 wherein the sample is a biopsy sample.
55. (amended once) An antibody reagent according to claim 51 or 52 wherein the P2X antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.

Applicant: Slater *et al.*

Attorney Reference No. BSW-1

56. (amended once) An antibody reagent according to claim 51 or claim 52 wherein the antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, or P2X<sub>7</sub>.

*Pursuant to 37 CFR 1.121(c)(1)(ii), a marked up version of the claims showing the changes made appears as Appendix A of this Amendment.*


### REMARKS

Applicants have amended the claims herein so as to clarify and more particularly indicate the claimed subject matter. The cancellation of and/or amendments to the claims are being made solely to expedite prosecution of this application. Applicant reserves the option to  
5 further prosecute the same or similar claims in this or in another patent application. No new matter is added. *After entry of this amendment, claims 1-6 and 8-56 are in the case.*

### CONCLUSION

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding these  
10 amendments and remarks, the Examiner is encouraged to contact either of the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529  
15 Nicholas P. Triano III, Reg. No. 36,397  
Attorneys for Applicants  
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY  
and POPEO, P.C.  
One Financial Center  
20 Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: October 22, 2001

531 Rec'd PC.

22 OCT 2001

**Appendix A: marked up version of the claims showing the changes made**

2. (amended once) A method of determining the aetiology of carcinogenesis in a mammal, comprising detecting the P2X purinergic receptor expression profile of cells and/or tissue from the mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.
4. (amended once) A method according to claim 1 or claim 2 [any one of claims 1 to 3] wherein the cells are prostate tissue cells.
5. (amended once) A method according to claim 1 or claim 2 [any one of claims 1 to 3] wherein the cells are breast tissue cells.
6. (amended once) A method according to claim 1 or claim 2 [any one of claims 1 to 4] wherein the cells are obtained by biopsy.
8. (amended once) A method according to claim 1 or claim 2 [any one of claims 1 to 4] wherein the cells are obtained from a body fluid, from digital rectal examination exudate and/or from semen.
9. (amended once) A method according to claim 1 or claim 2 [any one of claims 1 to 8] wherein detection of the P2X purinergic receptor expression profile comprises use of an antibody reagent.
10. (amended once) A method according to claim 1 or claim 2 [any one of claims 1 to 4 or 6, 8 or 9] wherein the detection of the P2X purinergic receptor expression profile comprises use of a P2X antibody reagent specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
11. (amended once) A method according to claim 5 [or claim 7] wherein the detection of the P2X purinergic receptor expression profile comprises use of an antibody reagent specific for P2X<sub>2</sub> or P2X<sub>3</sub>.
14. (amended once) A method according to any one of claims 9, 12 or 13 [9 to 13] wherein the antibody reagent comprises a polyclonal antiserum.
15. (amended once) A method according to any one of claims 9, 12 or 13 [9 to 13] wherein the antibody reagent comprises a monoclonal antiserum.
16. (amended once) A method according to any one of claims 9, 12 or 13 [9 to 13] wherein the antibody reagent is a suite of polyclonal antibodies.
17. (amended once) A method according to any one of claims 9, 12 or 13 [9 to 13] wherein the antibody reagent is a suite of monoclonal antibodies.



19. (amended once) A method according to any one of claims 1, 2, 12 or 13 [2 to 18] wherein detection of the P2X receptor expression profile is by immunohistochemical means.
20. (amended once) A method according to any one of claims 1, 2, 12 or 13 [2 to 18] wherein detection of the P2X receptor expression profile is by ELISA.
- 5 21. (amended once) A method according to any one of claims 1, 2, 12 or 13 [1 to 18] wherein detection of the P2X receptor expression profile is by RIA.
22. (amended once) A method according to any one of claims 1, 2, 12 or 13 [1 to 18] wherein the detection of the P2X receptor expression profile is by Western bolt.
23. (amended once) A method according to any one of claims 1, 2, 12 or 13 [1 to 18] wherein  
10 detection of the P2X purinergic receptor expression is by detection of P2X purinergic receptor mRNA.
27. (amended once) Use according to claim 24 or claim 25 [any one of claims 24 to 26] wherein the P2X purinergic receptor antibody reagent comprises a polyclonal antiserum.
28. (amended once) Use according to claim 24 or claim 25 [any one of claims 24 to 26]  
15 wherein the P2X purinergic receptor antibody is a monoclonal antiserum.
29. (amended once) Use according to claim 24 [27] or claim 25 [28] wherein the P2X purinergic receptor antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
30. (amended once) Use according to claim 24 or claim 25 [claim 29] wherein the P2X  
20 purinergic receptor antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, or P2X<sub>7</sub>.
31. (amended once) Use according to claim 24 or claim 25 [any one of claims 24 to 26 or 28 to 30] wherein the P2X purinergic receptor antibody reagent is a suite of polyclonal antibodies.
32. (amended once) Use according to claim 24 or claim 25 [any one of claims 24 to 26 or 28  
25 to 30] wherein the P2X purinergic receptor antibody reagent is a suite of monoclonal antibodies.
37. (amended once) An isolated mammalian cell or tissue sample according to claim 34 [claim 35 or claim 36] wherein the P2X purinergic receptor-specific antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
- 30 38. (amended once) An isolated mammalian cell or tissue sample according to claim 34 [37] wherein the P2X purinergic receptor-specific antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, or P2X<sub>7</sub>.

39. (amended once) A kit for diagnosing a pre-neoplastic and/or neoplastic state in a mammal comprising components [means] for detection of P2X purinergic receptor expression profile in a sample comprising cells and/or tissue from the mammal and means for comparison of the expression level with a predetermined expression level.
- 5 40. (amended once) A kit according to claim 39 wherein one of the components is [the detection means comprises] an antibody reagent specific for a P2X purinergic receptor.
43. (amended once) A kit according to claim 41 or claim 42 wherein the P2X purinergic receptor antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
44. (amended once) A kit according to claim 41 or claim 42 [claim 43] wherein the antibody  
10 reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> or P2X<sub>7</sub>.
45. (amended once) A kit according to claim 40 [any one of claims 39 to 47] wherein the P2X purinergic receptor expression profile is detected by a colorimetric assay.
48. (amended once) A kit according to claim 39 [any one of claims 39 to 47] wherein the sample is a body fluid.
- 15 49. (amended once) A kit according to claim 39 [any one of claims 39 to 47] wherein the sample is a digital rectal examination exudate.
50. (amended once) A kit according to claim 39 [any one of claims 39 to 48] wherein the sample is a biopsy sample.
55. (amended once) An antibody reagent according to claim 51 or claim 52 [any one of  
20 claims 51 to 54] wherein the P2X antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
56. (amended once) An antibody reagent according to claim 51 or claim 52 [55] wherein the antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, or P2X<sub>7</sub>.

25

TRA 1584586v1

9/PRTS

10,019356

531 Rec'd PCT/PTL 22 OCT 2001

WO 01/06259

PCT/AU00/00363

- 1 -

**A METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR  
NEOPLASTIC STATES IN MAMMALS**

**TECHNICAL FIELD**

The present invention relates to methods of identifying pre-neoplastic and/or  
5 neoplastic states in mammals and in particular to a method for identifying pre-  
neoplastic and neoplastic cells in tissues and body fluids, based on differential  
expression of purinergic receptors in these cells.

**BACKGROUND**

When diagnosing cancer, cellular features in biopsy samples are taken into  
10 account such as, the degree of variability of cancer cell size and shape, the proportion  
of actively dividing cells and invasion into neighbouring structures. Commonly used  
histological stains are haematoxylin (primary stain) and eosin (counterstain) which  
differentially label subcellular elements. Other diagnostic methods employ antibodies  
to particular diagnostic molecules within (via intracellular epitopes) or on the surface  
15 of cells or tissues (via extracellular epitopes) which can be made visible for  
microscopic analysis eg, carcino-embryonic antigen (CEA). Some specific examples  
are discussed below.

**Prostate Cancer**

The incidence of prostate cancer in the Western world is increasing at an  
20 alarming rate, having more than doubled in the past five years. It has the highest  
incidence of any neoplasm, is second only to lung cancer as the most common cause  
of cancer death in men worldwide, and is the leading cause of death in Australia [1].  
Benign prostatic hyperplasia (BPH) is common in men over 50 and is a possible  
precursor of prostatic intraepithelial neoplasia (PIN), itself a precursor to prostate

. WO 01/06259

PCT/AU00/00363

- 2 -

cancer. Postmortem studies indicate that 70% of men have malignant cells in their prostate by the time they reach 80 [2]. This disease is characterised by a striking racial variation and is most prevalent in African-Americans, intermediate in Caucasians, slightly lower in Latinos, and least prevalent in Asians. In the latter group, it is nevertheless the most rapidly increasing form of neoplasm. Until recently, it was not clear if these differences were due to racial genetic variation or diet. Studies have now shown that diet is a primary influencing factor [3].

#### **Current diagnosis and treatment of prostate cancer**

Despite the gravity of this condition, diagnostic methods are few and imprecise. Current methods for assessing prognosis such as digital rectal examination (DRE), ultrasound, prostatic acid phosphatase levels, androgen ablation, prostate specific antigen (PSA) density, PSA velocity, PSA age-specific reference ranges and Gleason histopathological grading, can fail to provide reliable predictive information regarding the clinical outcome of prostate cancer [4]. For instance, studies have shown that DRE results in a 36.9% false negative rate [5]. PSA is a 33-kDa serine protease that is associated with a number of tissues besides prostate [6], is up-regulated by androgens, glucocorticoids and progestins and is thought to be involved in the regulation of growth factors. Unfortunately, serum PSA levels have an incidence of 23% false negative and 36.7% false positive diagnoses [6]. It has even been suggested that more than half of new screen-detected cases are in fact false positives [7]. Attempts to improve screening methods by the introduction of additional tests such as PSA density, velocity, and age-specific reference ranges has been equivocal. One study has shown that applying an age-specific PSA reference range that increases the upper limit of normal PSA to 4.5 ng/mL results in the failure

WO 01/06259

PCT/AU00/00363

- 3 -

to detect a substantial number of clinically significant cancers [8]. Given this uncertainty, prostate biopsy is often performed to confirm malignancy but this test also has a highly unsatisfactory 23% incidence of false-negative diagnosis [9].

Treatment selection is largely dependent on clinical staging based on  
5 microscopic analysis of tissue sections [10]. This technique depends on judgment and considerable experience in relating histological appearance to clinical outcome. Unfortunately, prostate cancer tissue is notoriously heterogeneous and a vital diagnostic feature may easily be missed in the section being examined. To further complicate the situation, there have been no randomised and controlled trials to  
10 examine the outcomes of surgery and radiotherapy [2]. Treatment choices include radical prostatectomy, radiation therapy, androgen deprivation and "watchful waiting". A definitive answer to the question of "watchful waiting" versus radical intervention awaits the conclusion of the prostate cancer intervention-versus-observation trial [11]. The consequences to the patient of these decisions are serious.  
15 Radical prostatectomy for instance, often results in incontinence, impotence, bladder neck stricture and depression [12]. Clearly, improved markers that reliably differentiate between benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic cancer are urgently needed.

## 20 The role of P2X receptors in cancer

Neurotransmitters such as noradrenalin and acetylcholine act not only in the synapse and neuromuscular junction but also on transmitter-specific cell receptors in a wide variety of tissues and organs. These receptors are pore-like transmembrane channels that introduce ions into the cell. Adenosine triphosphate (ATP), best known

WO 01/06259

PCT/AU00/00363

- 4 -

as the molecular currency of intracellular energy stores, was first proposed as a peripheral neurotransmitter based on its ability to contract smooth muscle [13]. ATP acts in the same manner as other neurotransmitters and can activate both the (relatively slow) G protein-coupled tissue receptors (P2Y), the more recently characterised (fast) ligand-gated purinergic (P2X<sub>1,7</sub>) ion channels and can also act as a co-transmitter. Despite its relatively recent discovery, it is likely that the purinergic transmitter system developed very early in evolution [14].

There are currently 7 genetically distinct P2X receptor subtypes. They are as widely distributed as receptors of the cholinergic and adrenergic systems and are found in most mammalian cells [14]. These receptors constitute a new class of fast-response, membrane-bound, ligand-gated, calcium-permeable, cation-selective channels that are activated by extracellular ATP from nerve terminals or a local tissue source [15-18]. They are predominantly permeable to calcium ions but also admit other cations, such as potassium and sodium, thereby mediating depolarisation [19]. For instance, in lung epithelia, P2X channels stimulate Cl<sup>-</sup> channel up-regulation, K<sup>+</sup> secretion and inhibit Na<sup>+</sup> absorption (21). ATP can stimulate both DNA synthesis and cell proliferation via the up-regulation of the P2X receptors [14]. This function is linked to stimulation of phospholipase C and ionic calcium release from inositol-phosphate-sensitive intracellular stores, as well as other signal transduction pathways. These actions are potentiated by the synergistic action of ATP with polypeptide growth factors [20]. The influx of calcium through the P2X receptors also triggers the secretion of other neurotransmitters, serves as a signal for the activation of calcium-dependent potassium channels, inactivates other calcium channel types,

**WO 01/06259**

**PCT/AU00/00363**

- 5 -

regulates endocytotic retrieval of synaptic vesicle membranes, enhances the synthesis of neurotransmitters, regulates pools of synaptic vesicles available for secretion and triggers several forms of synaptic plasticity. The variety of responses to a single stimulation of P2X receptors suggests there are many calcium-activated pathways [21].

Extracellular ATP, acting via the purinergic receptors, also has a direct anticancer effect on human breast cancer cells, prostate carcinoma cells, human adenocarcinoma cells and fibroblast cell lines. Cytotoxic T lymphocytes and natural killer (NK) cells release ATP when they attack tumour cells [22]. Only transformed cell growth is inhibited, by inducing S phase block, apoptosis, increased permeability to nucleotides, sugar phosphates, ions and synergy with other anticancer agents. None of these effects are noted on untransformed cells [14].

Curiously, tumour cells are known to contain exceptionally high levels of ATP [23]. Adenosine and ATP both increase intratumour blood flow by stimulating nitric oxide synthesis from the endothelium, thus inducing potent vasodilation [24]. In this case ATP acts through P2Y receptors (26). Nitric oxide release is also linked to P2X receptor function. For instance, 90% of the nitric oxide synthase activity found in non-pregnant sheep myometrium is calcium ion-channel dependent [25].

Epithelial adhesive proteins also play a major role in the spread of cancer [26].

20 In wound healing, cell injury signals propagate via extracellular P2X receptors and intercellular gap junctions, stimulating calcium ion-induced wave propagation [27]. Intracellular calcium ions admitted by the P2X channels trigger the transport of membrane-bound organelles along microtubules, remodelling of the ECM and up-regulation of the adhesion molecule E-cadherin [28]. The myoepithelial cells found

WO 01/06259

PCT/AU00/00363

- 6 -

in prostatic epithelial acinar exert important paracrine effects on carcinoma cells both *in situ* and *in vitro*. Cancer cells are also affected by high expression of ECM molecules, proteinase inhibitors and angiogenic inhibitor [29]. During metastatic invasion, extracellular calcium influx activates membrane-associated metalloproteinases that facilitate tissue penetration by invasive cells. Urokinase plasminogen activator has also been strongly implicated in the progression of several malignancies including breast and prostate cancer [30].

Current techniques for staging and diagnosing cancer need to be improved in order to provide more reliable results using relatively simple technology. It would also be advantageous to have a diagnostic method amenable to automation.

It is an object of the present invention to provide a method of identifying pre-neoplastic and/or neoplastic cells which will overcome or substantially ameliorate at least some of the deficiencies of the prior art or will provide a useful alternative.

#### SUMMARY OF THE INVENTION

The purinergic nervous system operates in parallel with the better known but slower acting adrenergic and cholinergic nervous systems. Like them, it operates in the brain, synapse, neuromuscular junction, peripheral nervous system and smooth muscle. The transmitter substance activating these fast-acting ligand-gated cation receptor channels is ATP, which acts by triggering purinergic receptors in tissues, resulting in a variety of metabolic responses including an influx of ions into the cell.

A unique suite of highly specific antibodies able to differentiate between the extracellular domains of each of the P2X purinergic receptor subtypes has been developed. These receptors are readily visualised using immunocytochemical methods and present in a variety of expression patterns such as cell surface, tubular



WO 01/06259

PCT/AU00/00363

- 7 -

and punctate labelling. It has surprisingly been shown that the expression of P2X receptors is characteristic for pre-cancer and cancer stages and also for tissue from young vs old mammals. These changes are accompanied by marked differences in growth, extracellular matrix, metabolic and innervation factors as well as increases in subepithelial ionic calcium and microtubules. The invention therefore provides a new tool with which to diagnose pre-cancerous conditions, (such as hyperplasia), stage cancer and to investigate the basic physiology and aetiology of carcinogenesis.

According to a first aspect, the invention provides a method of staging and/or diagnosing pre-neoplastic and/or neoplastic states in a mammal, comprising detection of the P2X purinergic receptor expression profile of cells and/or tissue from said mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

According to a second aspect, the invention provides a method of determining the aetiology of carcinogenesis in a mammal, comprising detection of the P2X purinergic receptor expression profile of cells and/or tissue from the mammal and comparison of the profile with a predetermined expression profile of normal cells and/or tissue.

According to a third aspect, the present invention provides a method of diagnosing prostate cancer in a subject, comprising detecting the expression profile of P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, and/or P2X<sub>7</sub> purinergic receptors in prostate cells and/or tissue from the subject using P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> and/or P2X<sub>7</sub> antibody respectively, wherein an increase in the intensity of the P2X purinergic receptor expression profile in the prostate cells and/or tissue, compared to the expression profile of prostate cells and/or



WO 01/06259

PCT/AU00/00363

- 9 -

According to a ninth aspect, the invention provides an antibody reagent specific for a P2X purinergic receptor, wherein the reagent is capable of differentiating between pre-neoplastic or neoplastic cells and/or tissue and normal cells and/or tissue.

5 According to a tenth aspect, the invention provides an antibody reagent specific for a P2X purinergic receptor when used to differentiate between pre-neoplastic or neoplastic cells and/or tissue and normal cells and/or tissue.

According to an eleventh aspect, the invention provides an antibody reagent specific for P2X purinergic receptor when used to differentiate between functional  
10 and non-functional P2X receptors in cells and/or tissue.

Preferably the mammal is a human although it will be clear to the skilled addressee that the method may be applied to any mammal. Preferably the cells are prostate tissue and/or cells or breast tissue and/or cells. The cells may be obtained by biopsy but may also be obtained from a body fluid or, in the case of prostate tissue  
15 and/or cells, from digital rectal examination exudate or from semen.

Preferably the antibody reagent comprises a polyclonal antiserum. Preferably the P2X antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub> receptors, most preferably P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> or P2X<sub>7</sub> receptors. It will be clear to those skilled in the art that the antibody reagent may be a suite of antibodies that  
20 may be polyclonal or monoclonal. It will also be clear to those skilled in the art that the suite of P2X receptor antibodies may comprise any combination of the P2X receptor subtypes, and in particular the combination of P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> and P2X<sub>7</sub>.

Preferably detection of P2X receptor expression profile is by immunohistochemical means. It will be clear to the skilled addressee that the P2X

WO 01/06259

PCT/AU00/00363

- 10 -

receptors may be detected by other means including ELISA, RIA or similar immunological techniques, depending on the source of the cell or tissue sample and the reagents available. Preferably, the P2X receptors are detected by a colorimetric assay. It will also be clear to those skilled in the art that Western blotting techniques and detection of P2X purinergic receptor mRNA may be useful in determining the P2X receptor expression profile.

In the context of the present invention, the term "pre-neoplastic cells" comprises cells that are hyperplastic or hypertrophic.

In the context of the present invention the term "suite of antibodies" comprises polyclonal antibodies which contain several different antibodies specific for the same or different antigens and which are able to specifically differentiate between each of the P2X receptor subtypes. When the antibodies are monoclonal, the term "suite of antibodies" also comprises a panel of antibodies able to specifically differentiate between each of the P2X receptor subtypes.

In the context of the present invention, detection of an "expression profile" comprises detection of a pattern or intensity of expression.

Unless the context clearly requires otherwise, throughout the description and the claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

#### **BRIEF DESCRIPTION OF FIGURES**

Figure 1 shows an example of the level of P2X<sub>1</sub> labelling in a biopsy sample taken from a normal human prostate (left) and from a patient with advanced prostate cancer (right).

WO 01/06259

PCT/AU00/00363

- 11 -

Figure 2 shows a comparison of prostate epithelium (E) from a young (12 week) rat (left), and tissue from an aged rat (18 months; right). The aged tissue shows marked hyperplasia.

Figure 3 shows an example of P2X<sub>1</sub> labelling in normal breast (right) and of the substantial down-regulation in breast tumour tissue (left).

Figures 4a, b, d and e show core biopsies from a 71-year old man with increasing PSA. Diagnosis - BPH. The H&E stain (4a) shows mild hyperplasia in the apical epithelium (arrow) of the prostatic acini (A). Figure 4d is a high-power micrograph of this area (arrow). Labelling with anti-P2X in the same area (4b) shows the complete de-expression of P2X receptors that is characteristic of BPH (4b-arrow). Figure 4e is a high-power micrograph of this area showing complete P2X de-expression in the mildly hyperplastic epithelium (4e-arrow). Figure 4c. Section of core biopsy from a 69-year old man. PSA unknown. This case was also diagnosed as BPH by H&E stain (not shown) but features distinctive Stage 1 P2X labelling, as characterised by prominent epithelial nuclei (PEN) (4c-arrow). Figure 4f is a high-power micrograph of these densely-labelled nuclei (4f-arrow), as shown in Figure 4c. Figures 4a and 4d, H&E stain. Figures 4b, c, e and f, anti-P2X immunoperoxidase label. No counterstain. Bar for low power micrographs (4a, b and c) is 1cm = 150  $\mu$ m. Bar for high power micrographs (4d, e and f) is 1 cm = 40  $\mu$ m.

Figures 5a-c show core biopsies (supplied as 3 cores) from a 57-year old man with increasing PSA. Two cores were diagnosed as containing areas of BPH adjacent to areas of advanced cancer, Gleason score 8. Figure 5a shows an area of BPH with no cancerous markers (5a-arrow) stained with H&E. Figure 5b is a serial section from the same block labelled with P2X<sub>1</sub> antibody. The P2X labelling is characteristic of

WO 01/06259

PCT/AU00/00363

- 12 -

translocation Stage 2. The presence of these features, in tissue diagnosed by H&E staining as BPH, indicates not only the presence of preneoplastic change but that those changes are more advanced. Figure 5c is a high-power micrograph from a serial section of the acinus arrowed in Figure 5b. It depicts Stage 2 features as follows:

5 some PEN remains (N-arrowhead) but most labelling is now punctate and cytoplasmic (P-arrow). Previous experiments have shown that each puncta is an individually-labelled P2X receptor or small localised patch of receptors. The lateral plasma membranes are clearly labelled (L-arrow) and there is labelling in the apical epithelium (A-arrow).

10 Figures 5d-f show a core biopsy (3 cores) from an 81-year old man with a PSA of 8.1. In this case the diagnosis was infiltrating adenocarcinoma, Gleason score 6. H&E staining (Figure 5d) showed areas of both BPH and invasive cancer (prominent nucleoli, basement membrane invasion and abnormal acinal architecture). Figure 5e shows an increase in P2X labelling in the apical epithelium (arrow) but a  
15 general decrease in overall signal. A high-power micrograph (Figure 5f) shows these P2X labelling features to be typical of P2X translocation Stage 3. The labelling is less intense than that seen in Stage 2 (Figure 5b), due to a concentration of label in the apical epithelium. The nuclei are devoid of label except for the nuclear membrane (N-arrow). The label is homogeneous rather than punctate, and is mostly found on the  
20 apical epithelium (A-arrow). At the completion of the translocation process, P2X label was commonly concentrated in the apical epithelium after which it was de-expressed (D). Figures 5a and 5d, H&E stain. Figures 5b, c, e and f, P2X immunoperoxidase label. No counterstain. Bar for low power micrographs (5a, b, d and e) is 1cm = 150  $\mu$ m. Bar for high power micrographs (5c and f) is 1 cm = 40  $\mu$ m.

WO 01/06259

PCT/AU00/00363

- 13 -

Figures 6a-m show staining patterns in breast cancer biopsy tissue compared with normal tissue.

### DESCRIPTION OF THE INVENTION

A preferred embodiment of the invention will now be described by way of example only and with reference to the accompanying Figures.

#### **Example 1 - Immunohistochemical Procedure**

The immunohistochemical method used in this study was adapted from Barclay [31]. Sections with a thickness of 8  $\mu$ m were cut from unfixed, frozen tissue using a Reichert Jung 2800 Frigocut cryotome. Sections were air dried at room temperature for 1 hour, fixed for 12 hours in acetone at -20°C and air dried at room temperature for 1 hour prior to antibody labelling. They were then incubated at room temperature with one of either rabbit or sheep anti-P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub> antibody. After washing, sections were then incubated in the secondary antibody; a 1:30 dilution of HRP-conjugated goat anti-rabbit secondary antibody (Dako) for 30 mins for rabbit primaries and HRP-conjugated goat anti-sheep secondary antibody (Dako) for sheep primaries. Slides were again rinsed and then immersed in 15% diaminobenzidine tetrahydrochloride (DAB - Sigma) for 10 minutes. Sections were rinsed, air dried and mounted in DPX (Merck). Control slides were incubated in diluent buffer during the first incubation and then treated in the same manner as the experimental slides. Negative control slides were treated in the same manner as the experimental slides except that the primary antibody was replaced with non-immune serum.

**PCT/AU00/00363**

### Example 2 - Antibody Production

The consensus sequences of the rat P2X<sub>1</sub> [32], P2X<sub>2</sub> [33], P2X<sub>3</sub> [34], rat P2X<sub>4</sub> [35], rat P2X<sub>5</sub> [36], rat P2X<sub>6</sub> [36], rat P2X<sub>7</sub> [37], human P2X<sub>7</sub> [38], human P2X<sub>1</sub> [39], human P2X<sub>3</sub> [40], human P2X<sub>4</sub> [41] and human P2X<sub>5</sub> [42] cloned receptors were examined for suitable epitopes following the approach adopted in Hansen et al. [15]. The non-homologous epitopes corresponding to the segment Lys199-Cys217 used in rat P2X<sub>1</sub> were utilised in rat P2X<sub>3</sub>, rat P2X<sub>6</sub> and rat P2X<sub>7</sub>. Variations were applied to rat P2X<sub>4</sub> which used the sequence Ile235-Gly251 to which was attached a C-terminal Cys residue for cross-linking to a 6 kDa diphtheria toxin domain. The P2X<sub>2</sub> epitope was selected from a region within the C1 domain [15], Cys130-Gly153. The rat P2X<sub>5</sub> epitope was selected from a region closer to the second transmembrane domain but still extracellular (Lys314-Ile333 to which was added a C-terminal Cys also for conjugation). Although largely homologous with rat P2X<sub>4</sub>, cross-labelling of P2X<sub>4</sub> and P2X<sub>5</sub> did not occur. All antibodies against rat sequences were able to label corresponding human receptors. A separate epitope was used for the human P2X<sub>1</sub> and P2X<sub>7</sub> sequences. This was taken just C-terminal to the first transmembrane domain from Lys68-Val84 with an N-terminal Cys added for conjugation via a diphtheria toxin domain using maleimidocaproyl-N-hydroxysuccinimide. The epitope for human P2X<sub>3</sub> antibody was the equivalent sequence used for rat, while the epitopes for human P2X<sub>4</sub> and human P2X<sub>5</sub> were Cys270-Asn287 and Cys272-Ser288 respectively. All syntheses were carried out using standard t-BOC chemistry on an ABI synthesiser [43]. The peptide-antigen conjugates were suspended in water at 5 mg/mL and aliquots emulsified by mixing with Complete Freund's Adjuvant.



WO 01/06259

PCT/AU00/00363

- 15 -

Emulsion volumes of 1 mL containing 2 mg of peptide were injected intramuscularly with second, third, fourth and fifth immunisations followed at 2 week intervals using Incomplete Freund's Adjuvant. Final bleeds via venepuncture were obtained at 10-12 weeks, after it was established that adequate antibody titres had been obtained in the rabbits or sheep used for each epitope. The blood was incubated at 37°C for 30 min, and stored at 4°C for 15 h after which the serum was collected following centrifugation and stored at -20°C in small aliquots. Sera were tested with an ELISA assay for antibodies specific for each peptide [15]. The antibody titre, defined as the reciprocal of the serum dilution resulting in an absorbance of 1.0 above background in the ELISA assay, was in the range 75,000±4,000 compared with 225±25 for the pre-immune samples.

Affinity purification of each of the antibodies against the specific epitope for that antibody resulted in reduced background but identical labelling trends.

### Example 3 - Specificity of antibodies

Each of the P2X antisera used has been shown to possess similar distributions in many cases but with distinctly different distributions in other cases indicating that the antisera do not lack specificity. Specificity was demonstrated by affinity purification of the sera against the cognate peptides. To further verify antibody specificity, individual antibody such as the antibody to P2X<sub>1</sub> was added to cells transfected with the corresponding P2X<sub>1</sub> cDNA in the presence and absence of a 10mM concentration of the P2X<sub>1</sub> epitope. Immunolabelling and confocal imaging of the transfected *Xenopus* oocytes demonstrated that the expressed P2X<sub>1</sub> is located, as expected, within the cell membrane and the presence of a 10mM concentration of the

WO 01/06259

PCT/AU00/00363

- 16 -

cognate peptide as an absorption control resulted in the blocking of P2X<sub>1</sub> staining [18].

Individual specificity of all other antibodies has been similarly demonstrated.

#### **Example 4 - Preparation of tissue for ultrastructural examination of morphology**

5 Tissue was processed for morphological examination as follows: sections of approximately 3mm X 3mm in size were fixed in 2.5% glutaraldehyde in 0.1M Tris buffer pH 7.2 for 1 hour. They were then washed and post fixed in 2% aqueous osmium tetroxide for 2 hours. After further washing, the tissue was dehydrated in a graded series of alcohols and embedded in Spurr's resin. Curing was carried out at  
10 50°C for 18 hours. 100nm sections were then cut with a diamond knife, stained with uranyl acetate and Reynolds lead citrate in the usual manner and examined in a Phillips 400 transmission electron microscope.

#### **Example 5 - Ultrastructural Immunocytochemistry**

The method of Slater [44] was used. In short, thin sections (100nm) were cut  
15 and retrieved on 300 mesh nickel grids. After incubation in blocking solution (1% BSA in PBS) for 30 min, the sections were placed on the surface of a drop of the blocking solution (with the addition of 0.05% Tween 20) containing HRP-conjugated goat anti-rabbit secondary antibody or HRP-conjugated goat anti-sheep secondary antibody (diluted 1:100) for 1 h at room temperature. Grids were then rinsed three  
20 times for 10 min in PBS and placed on drops of goat anti-rabbit secondary antibody conjugated to 10 nm gold (Nanoprobe) for 1 h at room temperature. The grids were then washed twice with PBS followed by one wash with distilled water, for 10 min each and then placed in the vapour of 2% aqueous osmium tetroxide for 1 minute. Sections were then stained with aqueous uranyl acetate solution for 20 min, lead

WO 01/06259

PCT/AU00/00363

- 17 -

citrate for 10 min, rinsed twice for 10 min in distilled water and examined with a Phillips 400 electron microscope at 80 kV.

**Example 6 – P2X receptors in human cancer tissue**

In a study of 4 normal and 6 human prostate cancer cases, P2X<sub>1</sub>, P2X<sub>3</sub>, and P2X<sub>4</sub> subtypes were markedly increased in human prostate cancer tissue. There was no labelling at all for these subtypes in normal tissue. The labelling patterns for P2X<sub>1</sub> (Figure 1) in the cancerous tissue were particularly interesting in that there was a greater proportion of labelled acinar epithelial cells with each stage of prostate disease, suggesting a direct correlation between neoplastic transformation and the extent of P2X<sub>1</sub> acinar labelling. P2X<sub>3</sub> was also increased in some prostate cancer cells (results not shown). There was very little or no labelling for P2X<sub>5</sub> in normal tissue.

**Example 7 – P2X receptors, growth, innervation, and metabolic factors, ionic calcium modulation in young vs aged Wistar rats**

**P2X receptors and apoptosis:**

Studies comparing prostates from four 12 week-old rats and four 1.5 year-old rats resulted in the detection of a marked increase in epithelial hyperplasia in the aged rats, resembling BPH in humans (Figure 2). As with the human cancer tissue, P2X<sub>1</sub>, P2X<sub>3</sub>, and P2X<sub>4</sub> receptors and tyrosine kinase A receptor antibody were up-regulated in the prostatic epithelium of aged rats, when compared with that of young rats. As previously discussed, this indicates an increase in protein phosphorylation (activation), DNA synthesis, intracellular microtubule expression (organelle transport), up-regulation of adjacent receptors for other neurotransmitters, cell proliferation and an influx of ions (primarily ionic calcium) into the epithelial cells

WO 01/06259

PCT/AU00/00363

- 18 -

indicating apoptosis. An increase in alpha (1B) (voltage-gated calcium channel), and a reduction in the calcium-regulating hormone stanniocalcin was also observed in the aged rat prostates. PDGF and IGF-1 both inhibit apoptosis and were decreased in the aged rats [45]. Thus, the aged rat prostate undergoes apoptosis and similar changes in P2X receptor expression as human prostate cancer tissue, and therefore may be used to investigate prostate cancer aetiology.

**Innervation, other receptors and metabolic factors:**

In the aged rats, there was an increase in microtubular structures in the fibromuscular septa subjacent to the prostatic epithelium. These structures appeared similar in micrographs depicting the apoptosis-associated purinergic receptors P2X<sub>1</sub>, P2X<sub>2</sub>, ionic calcium, and the innervation factors VAMP, muscarinic receptor (M2), SV-2, SNAP-25, S100, and transferrin receptor, all of which were up-regulated in the aged rats. Alpha (1B) voltage-gated calcium channels and tyrosine kinase A receptors were also up-regulated in the aged rats. Stanniocalcin was down-regulated while the P2X<sub>1</sub> and P2X<sub>2</sub> apoptotic calcium channel receptors were up-regulated. These data indicate an increase of calcium ion inflow, metabolic rate, microtubule transport and innervation of the prostatic epithelium in the aged rats, and also suggest that this model could be used to investigate human prostate cancer.

**Example 8 - Breast cancer cell lines**

In 6 breast cancer cell lines supplied as frozen sections, P2X<sub>1</sub>, P2X<sub>3</sub>, and P2X<sub>4</sub> purinergic subtypes were labelled using the same techniques employed in the labelling of prostate tissues. The labelling pattern (Figure 3) was suggestive of the labelling patterns seen in both human prostate cancer tissue (Figure 1) and the prostate of the male aged Wistar rat (Figure 2).

WO 01/06259

PCT/AU00/00363

- 19 -

**Example 9 - Prostate cancer diagnoses (Figures 4a-f and 5a-f)**

The expression characteristics of the purinergic receptor calcium channels (P2X<sub>1-7</sub>) were examined in normal and pathological prostate tissue from 65 cases representing each stage of prostate disease: normal, BPH, preneoplastic and cancerous (Gleason's grade 5-9). Clear translocation features were noted in tissue labelled with P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> and P2X<sub>7</sub>. After a lengthy process of optimisation and standardisation of P2X antibody production and labelling protocols, a standardised protocol was developed. A mixture of P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> and P2X<sub>7</sub> subtypes at a concentration of 0.5 µg / mL IgG each, diluted 1:100 with PBS, proved to be the best reagent for demonstrating the translocation features described. P2X<sub>4</sub>, P2X<sub>5</sub> or P2X<sub>6</sub> labelling was of lesser significance. Using this reagent to label tissue sections from each category of prostate cancer it was found that there was a sequential expression and translocation of P2X labelling from the nuclei to the cytoplasm and lateral plasma membranes, ultimately expressing primarily in the apical epithelium, as cancer progressed (Figs 4f, 5c, 5f).

P2X labelling was completely de-expressed in BPH tissue (Figs 4b, 4e). Preneoplastic P2X translocation occurred in three distinct stages. Stage 1 was characterised by dense, prominent P2X-labelled epithelial nuclei (PEN) on a pale background (Figs 4c, 4f). Stage 2 featured a progressive de-expression of PEN and the appearance of dense and markedly punctate cytoplasmic labelling, nuclear membrane and lateral plasma membrane labelling, and an increasing signal on the apical epithelium (Figs 5b, 5c). Stage 3 was represented by nuclei labelled only on the nuclear membrane (NO), no cytoplasmic signal, homogeneous rather than punctate labelling, and a dense label in the apical epithelium (Figs 5e, 5f).

WO 01/06259

PCT/AU00/00363

- 20 -

In the present study, 56% of cases diagnosed as normal or BPH by haematoxylin and eosin (H&E) staining, showed Stage 1 or Stage 2 P2X labelling. The remaining cases, ranging from Gleason score G5 to G9, had P2X Stage 2 or 3 labelling features. Stage 3 labelling was always accompanied by the histological features of cancer (Fig 5e). True non-neoplastic BPH tissue was easily distinguished by the complete de-expression of all P2X subtypes in the epithelium and stroma. We propose that biopsy tissue that has been histologically diagnosed as normal but displays P2X labelling features, may be in the process of early (preneoplastic) transformation at a metabolic level. The demonstration of Stage 2 features in 'normal' tissue suggests that the preneoplastic process is more advanced in that tissue. The P2X labelling features described are stage-specific and uniform throughout the entire area of cells representative of each histological classification. In cores that contained both BPH and cancer areas, P2X labelling was clearly and uniformly demarcated into either BPH or one of the cancer labelling patterns. It is proposed that this technique can be used to exclude (and reassure) patients with non-neoplastic prostatic conditions from those with early cancer and also identify rapidly-developing preneoplasia, that may lead to malignancy. This information may permit earlier and more accurate treatment decisions.

#### **Example 10 - Breast cancer diagnoses**

Subtypes P2X<sub>2</sub>, P2X<sub>3</sub>, and P2X<sub>7</sub> are significantly down-regulated in breast cancer biopsy tissue compared with normal. Subtypes P2X<sub>1</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, and P2X<sub>6</sub> were unlabeled in both the normal and cancerous tissue. Tissue was pre-incubated with 3% hydrogen peroxide and 5% horse serum to suppress endogenous peroxidase activity. Examples of the staining patterns are shown in Figs 6a-m.

WO 01/06259

PCT/AU00/00363

- 21 -

Although the invention has been described with reference to specific examples, it will be appreciated by those skilled in the art that the invention may be embodied in many other forms.

WO 01/06259

PCT/AU00/00363

- 22 -

**References**

1. Lian FR, Bhuiyan M, Li YW, Wall N, Kraut M, and Sarkar FH, 1998 Genistein-Induced G(2)-M Arrest, P21(Waf1) Upregulation, and Apoptosis in a Non-Small-Cell Lung Cancer Cell Line. *Nutr. & Cancer*. 31:184-191.
- 5 2. Hoey J, 1998 Prostate cancer: progress and perplexity. *CMAJ* 159:1-3.
3. Kolonel LN, Nomura AM, Hinds MW, Hirohata T, Hankin JH, and Lee J, 1983 Role of diet in cancer incidence in Hawaii. *Cancer Res*. 43:2397s-2402s.
4. Festuccia C, Vincentini C, di Pasquale AB, Aceto G, Zazzeroni F, Miano L, and Bologna M, 1995 Plasminogen activator activities in short-term tissue cultures of  
10 benign prostatic hyperplasia and prostatic carcinoma. *Oncol. Res*. 7:131-138.
5. Saxena S, Mohanty NK, and Jain AK, 1997 Screening of prostate cancer in males with prostatism. *Ind. J. Pathol. Micro*. 40:441-450.
6. Diamandis EP and Yu H, 1997 Nonprostatic sources of prostate-specific antigen. *Urol. Clin. Nth. Am*. 24:275-282.
- 15 7. Weyler J, 1999 Prostate cancer: screening or watchful waiting? *Ann. Oncol*. 9:9-11.
8. Bassler TJ, Orozco R, Bassler IC, Odowd GJ, and Stamey TA, 1998 Most Prostate Cancers Missed By Raising the Upper Limit of Normal Prostate-Specific Antigen For Men in Their Sixties Are Clinically Significant. *Urol*. 52:1064-1069.
- 20 9. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, and Fair WR, 1998 Incidence and clinical significance of false-negative sextant prostate biopsies. *J. Urol*. 159:1247-1250.
10. Gao X, Porter AT, Grignon DJ, Pontes JE, and Honn KV, 1997 Diagnostic and prognostic markers for human prostate cancer. *Prostate* 31:264-281.



WO 01/06259

PCT/AU00/00363

- 23 -

11. Small EJ, 1997 Prostate cancer. *Curr. Opin. Oncol.* 9:277-286.
12. Moul JW, Mooneyhan RM, Kao TC, McLeod DG, and Cruess DF, 1998  
Preoperative and Operative Factors to Predict Incontinence, Impotence and Stricture  
After Radical Prostatectomy. *Prost. Can. & Prost. Dis.* 1:242-249.
- 5 13. Drury A and Szent-Gyorgyi A, 1929 The physiological activity of adenine  
compounds with special reference to their action upon the mammalian heart. *J.*  
*Physiol.* 68:213-237.
14. Abbracchio M and Burnstock G, 1998 Purinergic signalling: pathophysiological  
roles. *Jap. J. Pharmacol.* 78:113-145.
- 10 15. Hansen MA, Barden JA, Balcar VJ, Keay KA, and Bennett MR, 1997 Structural  
motif and characteristics of the extracellular domain of P2X receptors. *Biochem.*  
*Biophys. Res. Comm.* 236:670-675.
16. Hansen MA, Balcar VJ, Barden JA, and Bennett MR, 1998 The distribution of  
single P2X1-receptor clusters on smooth muscle in relation to nerve varicosities in the  
15 rat urinary bladder. *J. Neurocytol.* 27:529-539.
17. Hansen M, Dutton J, Balcar V, Barden J, and Bennett M, 1999 P2x (purinergic)  
receptor distributions in rat blood vessels. *J. Auton. Nerv. Syst.* 75:147-155.
18. Dutton J, Hansen M, Balcar V, Barden J, and Bennett MR, 1998 Development of  
P2X receptor clusters on smooth muscle cells in relation to nerve varicosities in the  
20 rat urinary bladder. *J. Neurocytol.* in press.
19. Filipovic DM, Adebajo OA, Zaidi M, and Reeves WB, 1998 Functional and  
molecular evidence for P2x receptors in L1c-Pk1 Cells. *Am. J. Physiol.* 43:F1070-  
F1077.

WO 01/06259

PCT/AU00/00363

- 24 -

20. Abbracchio M, 1996 P1 and P2 receptors in cell growth and differentiation. *Drug. Dev. Res.* 39:393-406.
21. Augustine G, Betz H, Bommert K, Charlton M, DeBello W, Hans M, and Swandulla D, Molecular pathways for presynaptic calcium signalling, in *Molecular and Cellular Mechanisms of Neurotransmitter Release*, L. Stjarne, *et al.*, Editors. 5 1994, Raven Press: New York. p. 139-155.
22. Di Firgilio F, Pizzo P, Zanovello P, Bronte V, and Collavo D, 1990 Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. *Immunol. Today* 11:274-277.
- 10 23. Siems W, Grune T, Schmidt H, Tikhonov Y, and Pimenov A, 1993 Purine nucleotide levels in host tissues of Ehrlich ascities tumor-bearing mice in different growth phases of the tumor. *Cancer Res.* 53:5143-5147.
24. Natori Y, Moriguchi M, Fujiwara S, Takeshita I, Fukui M, Iwaki T, and Kanaide H, 1992 Effects of L-NMMA and L-NNA on the selective ATP-induced enhancement 15 of intratumoral blood flow. *J. Cereb. Blood Flow Metab.* 12:120-127.
25. Figueroa JP and Massmann GA, 1995 Estrogen increases nitric oxide synthase activity in the uterus of nonpregnant sheep. *Am. J. Obstet. Gynecol.* 173:1539-1545.
26. Rabbani SA and Xing RH, 1998 Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. *Int. J. Oncol.* 20 12:911-920.
27. Ciccarelli R, Di Iorio P, Ballerini P, Ambrosini G, Giuliani P, Tibone G, and Caciagli F, 1994 Effects of exogenous ATP and related analogues on the proliferation rate of dissociated primary cultures of rat astrocytes. *J. Neurosci. Res.* 39:556-566.

WO 01/06259

PCT/AU00/00363

- 25 -

28. Potter SW, Gaza G, and Morris JE, 1996 Estradiol induces E-cadherin degradation in mouse uterine epithelium during the estrous cycle and early pregnancy. *J. Cell. Physiol.* 169:1-14.
29. Kedeshian P, Sternlicht MD, Nguyen M, Shao ZM, and Barsky SH, 1998 Humatrix, a Novel Myoepithelial Matrical Gel With Unique Biochemical and Biological Properties. *Cancer Lett.* 123:215-226.
30. Dethlefsen SM, Raab G, Moses MA, Adam RM, Klagsbrun M, and Freeman MR, 1998 Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. *J. Cell. Biochem.* 69:143-153.
31. Barclay A, 1981 The localisation of populations of lymphocytes defined by monoclonal antibodies in rat lymphoid tissues. *Immunology* 42:593-600.
32. Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant A, and Buell G, 1994 A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP [see comments]. *Nature* 371:516-519.
33. Brake AJ, Wagenbach MJ, and Julius D, 1994 New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. *Nature* 371:519-523.
34. Lewis C, Neidhart S, Holy C, North RA, Buell G, and Surprenant A, 1995 Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons [see comments]. *Nature* 377:432-435.
35. Buell G, Collo G, and Rassendren F, 1996 P2X receptors: an emerging channel family. *Eur. J. Neurosci.* 8:2221-2228.
36. Collo G, North RA, Kawashima E, Merlo-Pich E, Neidhart S, Surprenant A, and Buell G, 1996 Cloning OF P2X5 and P2X6 receptors and the distribution and

WO 01/06259

PCT/AU00/00363

- 26 -

- properties of an extended family of ATP-gated ion channels. *J. Neurosci.* 16:2495-2507.
37. Surprenant A, Rassendren F, Kawashima E, North RA, and Buell GS, 735-738., 1996 The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). *Science* 272:735-738.
38. Rassendren F, Buell GN, Virginio C, Collo G, North RA, and Surprenant A, 1997 The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. *J. Biol. Chem.* 272:5482-5486.
39. Longhurst PA, Schwegel T, Folander K, and Swanson R, 1996 The human P2x1 receptor: molecular cloning, tissue distribution, and localization to chromosome 17. *Biochim. Biophys. Acta* 1308:185-188.
40. Garcia-Guzman M, Stuhmer W and Soto F, 1997 Molecular characterization and pharmacological properties of the human P2X3 purinoceptor *Brain Res. Mol. Brain Res.* 47, 59-66.
41. Garcia-Guzman M, Soto F, Gomez-Hernandez JM, Lund PE, and Stuhmer W, 1997 Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue. *Mol. Pharmacol.* 51, 109-118.
42. Le KT, Paquet M, Nouel D, Babinski K and Seguela P, 1997 Primary structure and expression of a naturally truncated human P2X ATP receptor subunit from brain and immune system *FEBS Lett.* 418, 195-199.
43. Barden JA, Cuthbertson RM, Jia-Zhen W, Moseley JM, and Kemp BE, 1997 Solution structure of parathyroid hormone related protein (residues 1-34) containing an Ala substituted for an Ile in position 15 (PTHrP[Ala15]-(1-34)). *J. Biol. Chem.* 272:29572-29578.

WO 01/06259

PCT/AU00/00363

- 27 -

44. Slater M, Patava J, Kingham K, and Mason RS, 1994 Modulation of growth factor incorporation into the extracellular matrix of human osteoblast-like cells in vitro by  $17\beta$  estradiol. Am. J. Physiol. 267:E990-E1001.
45. Kiess W and Gallaher B, 1998 Hormonal control of programmed cell death/apoptosis. Eur. J. Endocrinol. 138:482-491.
- 5

**CORRECTED VERSION**

- 28 -

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A method of staging and/or diagnosing pre-neoplastic and/or neoplastic states in a mammal, comprising detecting the P2X purinergic receptor expression profile of cells and/or tissue from said mammal and comparison of the profile with a predetermined  
 5 expression profile of normal cells and/or tissue.
2. A method of determining the aetiology of carcinogenesis in a mammal, comprising detecting the P2X purinergic receptor expression profile of cells and/or tissue from the mammal and comparison of the profile with predetermined expression profile of normal cells and/or tissue.
- 10 3. A method according to claim 1 or claim 2 wherein the mammal is a human.
4. A method according to any one of claims 1 to 3 wherein the cells are prostate tissue cells.
5. A method according to any one of claims 1 to 3 wherein the cells are breast tissue cells.
- 15 6. A method according to any one of claims 1 to 4 wherein the cells are obtained by biopsy.
7. A method according to claim 5 wherein the cells are obtained by biopsy.
8. A method according to any one of claims 1 to 4 wherein the cells are obtained from a body fluid, from digital rectal examination exudate and/or from semen.
- 20 9. A method according to any one of claims 1 to 8 wherein detection of the P2X purinergic receptor expression profile comprises use of an antibody reagent.
10. A method according to any one of claims 1 to 4 or 6, 8 or 9 wherein the detection of the P2X purinergic receptor expression profile comprises use of a P2X antibody reagent specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.

11. A method according to claim 5 or claim 7 wherein the detection of the P2X purinergic receptor expression profile comprises use of an antibody reagent specific for P2X<sub>2</sub> or P2X<sub>3</sub>.
12. A method of diagnosing prostate cancer in a subject, comprising detecting the  
5 expression profile of P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> and/or P2X<sub>7</sub> purinergic receptors in prostate cells and/or tissue from the subject using P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> and/or P2X<sub>7</sub> antibody respectively, wherein an increase in the intensity of the P2X purinergic receptor expression profile in the prostate cells and/or tissue, compared to the expression profile of prostate cells and/or tissue from a prostate having benign prostate hyperplasia, is  
10 diagnostic of the presence of prostate cancer.
13. A method of diagnosing breast cancer in a subject comprising detecting the expression profile of P2X<sub>2</sub> or P2X<sub>3</sub> purinergic receptors in breast cells and/or tissue from the subject using P2X<sub>2</sub> or P2X<sub>3</sub> antibody respectively, wherein a decrease in the intensity of the P2X purinergic receptor expression profile in the breast cells and/or tissue  
15 compared to the expression profile of breast cells and/or tissue from the breast of a normal subject, is diagnostic of the presence of breast cancer.
14. A method according to any one of claims 9 to 13 wherein the antibody reagent comprises a polyclonal antiserum.
15. A method according to any one of claims 9 to 13 wherein the antibody reagent  
20 comprises a monoclonal antiserum.
16. A method according to any one of claims 9 to 14, wherein the antibody reagent is a suite of polyclonal antibodies.
17. A method according to any one of claims 9 to 13 or 15, wherein the antibody reagent is a suite of monoclonal antibodies.

**WO 01/06259**

**PCT/AU00/00363**

- 30 -

18. A method according to claim 16 or claim 17 wherein the suite of P2X receptor antibodies comprises a combination of the P2X receptor sub-types antibodies.
19. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by immunohistochemical means.
20. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by ELISA.
21. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by RIA.
22. A method according to any one of claims 1 to 18 wherein detection of the P2X receptor expression profile is by Western blot.
23. A method according to any one of claims 1 to 18 wherein detection of the P2X purinergic receptor expression is by detection of P2X purinergic receptor mRNA.
24. Use of a P2X purinergic receptor antibody reagent to stage and/or diagnose a pre-neoplastic and/or neoplastic state in a mammalian subject.
25. Use of a P2X purinergic receptor antibody reagent to determine the aetiology of carcinogenesis in a mammalian subject.
26. Use according to claim 24 or claim 25 wherein the mammal is a human.
27. Use according to any one of claims 24 to 26 wherein the P2X purinergic receptor antibody reagent comprises a polyclonal antiserum.
28. Use according to any one of claims 24 to 26 wherein the P2X purinergic receptor antibody is a monoclonal antiserum.
29. Use according to claim 27 or claim 28 wherein the P2X purinergic receptor antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.



WO 01/06259

PCT/AU00/00363

- 31 -

30. Use according to claim 29 wherein the P2X purinergic receptor antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> or P2X<sub>7</sub>.
31. Use according to any one of claims 26 to 27 or 29 and 30, wherein the P2X purinergic receptor antibody reagent is a suite of polyclonal antibodies.
- 5 32. Use according to any one of claims 24 to 26 or 28 to 30, wherein the P2X purinergic receptor antibody reagent is a suite of monoclonal antibodies.
33. Use according to claim 31 or claim 32 wherein the suite of P2X receptor antibodies comprises a combination of antibodies specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> and P2X<sub>7</sub>.
- 10 34. An isolated mammalian cell or tissue sample complexed with a P2X purinergic receptor-specific antibody reagent.
35. An isolated mammalian cell or tissue sample according to claim 34 wherein the P2X purinergic receptor-specific antibody reagent comprises polyclonal antiserum.
- 15 36. An isolated mammalian cell or tissue sample according to claim 34 wherein the P2X purinergic receptor antibody reagent comprises monoclonal antiserum.
37. An isolated mammalian cell or tissue sample according to claim 35 or claim 36 wherein the P2X purinergic receptor-specific antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
- 20 38. An isolated mammalian cell or tissue sample according to claim 37 wherein the P2X purinergic receptor-specific antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, or P2X<sub>7</sub>.
39. A kit for diagnosing a pre-neoplastic and/or neoplastic state in a mammal comprising means for detection of P2X purinergic receptor expression profile in a

WO 01/06259

PCT/AU00/00363

- 32 -

sample comprising cells and/or tissue from the mammal and means for comparison of the expression level with a predetermined expression level.

40. A kit according to claim 39 wherein the detection means comprises an antibody reagent specific for a P2X purinergic receptor.
- 5 41. A kit according to claim 40 wherein the P2X purinergic receptor antibody reagent comprises a polyclonal antiserum.
42. A kit according to claim 40 wherein the P2X purinergic receptor antibody reagent comprises a monoclonal antiserum.
43. A kit according to claim 42 wherein the P2X purinergic receptor antibody
- 10 reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
44. A kit according to claim 43 wherein the antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, or P2X<sub>7</sub>.
45. A kit according to any one of claims 39 to 44 wherein the P2X purinergic receptor expression profile is detected by a colorimetric assay.
- 15 46. A kit according to claim 45 wherein the assay is an ELISA.
47. A kit according to claim 45 wherein the assay is an RIA.
48. A kit according to any one of claims 39 to 47 wherein the sample is a body fluid.
49. A kit according to any one of claims 39 to 47 wherein the sample is a digital
- 20 rectal examination exudate.
50. A kit according to any one of claims 39 to 48 wherein the sample is a biopsy sample.

WO 01/06259

PCT/AU00/00363

- 33 -

51. An antibody reagent specific for a P2X purinergic receptor, wherein the reagent is capable of differentiating between pre-neoplastic or neoplastic cells and/or tissue and normal cells and/or tissue.
52. An antibody reagent specific for a P2X purinergic receptor when used to  
5 differentiate between functional and non-functional P2X receptors in cells and/or tissue.
53. An antibody reagent according to claim 51 or claim 52 wherein the antibody reagent comprises a polyclonal antiserum.
54. An antibody reagent according to claim 51 or claim 52 wherein the antibody  
10 reagent comprises a monoclonal antiserum.
55. An antibody reagent according to any one of claims 51 to 54 wherein the P2X antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, P2X<sub>4</sub>, P2X<sub>5</sub>, P2X<sub>6</sub> or P2X<sub>7</sub>.
56. An antibody reagent according to claim 55 wherein the antibody reagent is specific for P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub>, or P2X<sub>7</sub>.



10/019356

WO 01/06259

1/9

PCT/AU00/00363

**Fig 1**

The following figure shows an example of the level of P2X1 labeling in a biopsy sample taken from a normal human prostate (left) and from a patient with advanced prostate cancer (right).

**Normal Prostate****Prostate Cancer**

10/019356

PCT/AU00/00363

WO 01/06259

2/9

**Fig 2**


The following Figure shows that, compared with prostate epithelium (E) from a young (12 week) rat (left), tissue from an aged rat (18 months) shows marked hyperplasia (right).



CORRECTED VERSION

**Fig 3**

The following figure shows an example of P2X1 labelling in normal breast (right) and a substantial down-regulation in breast tumour tissue (left).



**Breast Tumour Tissue**



**Normal Breast Tissue**

10/019356

WO 01/06259

PCT/AU00/00363

4/9



Fig 4



10/019356

WO 01/06259

PCT/AU00/00363

5/9




Fig 6


10/019356

WO 01/06259

PCT/AU00/00363

6/9

Fig 6



(a) Low Power: normal tissue, P2X2 label.

Bars - 50µm.



(b) Low Power: breast cancer, P2X2.



(c) Low Power: normal tissue, H&amp;E stain.

Bars = 50µm.



(d) Low Power: breast cancer, H&amp;E stain.




10/019356

WO 01/06259

PCT/AU00/00363

8/9

Fig 6



10/019356

WO 01/06259

PCT/AU00/00363

9/9

Fig 6

(m) Control: normal tissue, bar = 50  $\mu$ m, erythrocytes with residual endogenous activity (arrow)

Express Mail Label No.: **EV054294798 US**  
 Date of Deposit: **MAY 21, 2001**

**PATENT APPLICATION**  
 Attorney Docket No. BSW-1

**COMBINED DECLARATION AND POWER OF ATTORNEY  
 FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a utility patent is sought on the invention entitled:

**A METHOD FOR IDENTIFYING PRE-NEOPLASTIC  
 AND/OR NEOPLASTIC STATES IN MAMMALS**

the specification of which was filed on **October 22, 2001**, as United States non-provisional application No. 10/019,356, and bearing Attorney Docket No. BSW-1.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

- ☒ I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Appln. Number	Country (if PCT, so indicate)	Filing Date (dd/mm/yy)	Priority Claimed	
			Yes	No
PP9911	Australia	21/04/99	X	
AU00/00363	PCT	26/04/00	X	

- ☐ I hereby claim the benefit under Title 35, United States Code, § 119(e) or §120 of any United States application(s), or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing

**Applicant: Slater et al.**  
**Filed: October 22, 2001**

date of the prior application and the national or PCT International filing date of this application:

<b>Application No.</b> (U.S.S.N.)	<b>Filing Date</b> (dd/mm/yy)	<b>Status</b> (Patented, Pending, Abandoned)

PCT International Applications designating the United States:

<b>PCT International Application No.</b>	<b>PCT Filing Date</b>	<b>Status</b>

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

38

<b>Attorney or Agent</b>	<b>Registration No.</b>	<b>Attorney or Agent</b>	<b>Registration No.</b>
Kevin Ainsworth	<u>39,586</u>	David E. Johnson	<u>41,874</u>
Ingrid Beattie	<u>42,306</u>	Christina Karnakis	<u>45,899</u>
William Belanger	<u>40,509</u>	Kristin E. Konzak	<u>44,848</u>
Charles E. Bell	<u>48,128</u>	Cynthia Kozakiewicz	<u>42,764</u>
Naomi Biswas	<u>38,384</u>	Barry Marenberg	<u>40,715</u>
Bradford C. Blaise	<u>47,429</u>	A. Jason Mirabito	<u>28,161</u>
Sean M. Coughlin	<u>48,593</u>	Michel Morency	Limited Recognition
David F. Crosby	<u>36,400</u>	Carol H. Peters	<u>45,010</u>
Christopher J. Cuneo	<u>42,450</u>	David Poirier	<u>43,007</u>
Brian C. Dauphin	<u>40,983</u>	Michael Renaud	<u>44,299</u>
Brett N. Dorny	<u>35,860</u>	Brian Rosenbloom	<u>41,276</u>
Marianne Downing	<u>42,870</u>	Robert J. Sayre	<u>42,124</u>
Ivor R. Elrifi	<u>39,529</u>	C. Eric Schulman	<u>43,350</u>
Heidi A. Erlacher	<u>45,409</u>	Gregory J. Sieczkiewicz	<u>48,223</u>
James G. Gatto	<u>32,694</u>	Thomas M. Sullivan	<u>39,392</u>
Richard Gervase	<u>46,725</u>	Janine Susan	<u>46,119</u>
Matthew J. Golden	<u>35,161</u>	Nicholas P. Triano III	<u>36,397</u>
John A. Harre	<u>37,345</u>	Howard Susser	<u>33,556</u>
Brian P. Hopkins	<u>42,669</u>	Raphael A. Valencia	<u>43,216</u>
Shane Hunter	<u>41,858</u>		

all of MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO PC, One Financial Center, Boston, Massachusetts 02111, as Applicant's attorneys with full power of substitution and revocation to take any and all action necessary with regard to the above-identified patent.

**Applicant: Slater et al.**  
**Filed: October 23, 2001**

Address all telephone calls to Ivor R. Elrifi, Esq. at telephone number 617/348-1747.

Address all correspondence to:

Ivor R. Elrifi, Esq.  
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.  
One Financial Center  
Boston, Massachusetts 02111


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or patent issued thereon.

1-00 X [Signature] X 25/2/02  
 Inventor's Signature Date  
 Full Name of Inventor: Michael Slater  
 Citizenship: Australia  
 Residence: Flat 3/511 Burwood Road, Belmore, New South Wales 2192, Australia AUK  
 Post Office Address: Same

2-00 X [Signature] X 22/2/2002  
 Inventor's Signature Date  
 Full Name of Inventor: Julian Barden  
 Citizenship: Australia  
 Residence: 48 Mawarra Crescent, Marsfield, New South Wales 2122, Australia AUK  
 Post Office Address: Same



United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

~~✗~~ *Scanned copy is best available.* Drawings too dark.